Shantel
Key Takeaways
- Trialogics, a prominent clinical trial software and services company, is bolstering its services by expanding its Remote Device Management capabilities.
- The company is opening a new office in London to address the ongoing clinical trial demands in the United Kingdom, following the changes brought about by Brexit.
- Trialogics is also preparing to establish an office in Sydney, Australia, in 2024 to cater to the needs of clients in the Asia-Pacific region.
- The company’s integrated logistics approach, coupled with services such as eConsent, IRT (RTSM), and eCOA, enhances clients’ ability to monitor sites, subjects, timelines, and expenses.
Advancing Clinical Trials Through Enhanced Device Management
Trialogics, a trailblazing clinical trial software and services company, has announced a strategic expansion of its services through the augmentation of its Remote Device Management capabilities. With a commitment to enhancing clinical trial processes and outcomes, Trialogics is setting its sights on offering even more comprehensive solutions to its clients.
As part of its global expansion efforts, Trialogics is opening a new office in London. This expansion aims to cater to the evolving landscape of clinical trials in the wake of Brexit. Prior to the UK’s departure from the EU, Trialogics’ office in Rome served the needs of sites across Europe. The new London office is a proactive step to ensure that the company continues to provide efficient support to its clients within the United Kingdom.
Moreover, recognizing the increasing demands of its existing clients in the Asia-Pacific region, Trialogics is preparing to establish a new office in Sydney, Australia, by mid-2024. This strategic move highlights Trialogics’ commitment to offering tailored solutions that cater to the unique needs of different geographical regions.
A Holistic Approach: Integration and Efficiency
At the core of Trialogics’ strategy is the integration of its services to provide a seamless and efficient experience for its clients. With an extensive portfolio that includes eConsent, IRT (RTSM), eCOA, and Remote Device Management, the company is positioned to offer a holistic solution that addresses various aspects of clinical trials.
“The integration of our services and the expansion of our international presence are critical steps in meeting the demands of an evolving industry. Our focus is on delivering valuable data that empowers our clients to monitor and manage clinical trial sites, subjects, timelines, and expenses,” explains Chris Gropp, CEO of Trialogics.
Empowering Clinical Trials Through Technology
One of the standout features of Trialogics’ approach is its deployment of Samsung devices with mobile data plans to clinical trial sites. These secure devices provide a gateway for sites to access the Trialogics system and other clinical trial services. From managing patients to uploading data to secure cloud storage, these devices play a pivotal role in streamlining the clinical trial process.
Furthermore, Trialogics’ devices are assigned to patients for various tasks, including completing questionnaires, diaries, and capturing additional data from other mobile devices. The data collected is then transmitted to a central database associated with the ongoing clinical trial, enabling clinicians to review the information in real time. This technological approach not only enhances the efficiency of clinical trials but also contributes to the quality and accuracy of data collection.
Pioneering Innovation: Focus on Security and Service Excellence
Trialogics’ commitment to innovation and service excellence is evident in its approach to mobile device management. Recognizing the need for improved mobile device management in the industry, Trialogics has developed technology that prioritizes both the security of devices and the delivery of exceptional clinical trial services.
“From the beginning, we have aimed to redefine mobile device management in the context of clinical trials. Our technology not only ensures security but also empowers clinicians and researchers with valuable data insights,” says Gropp.
A Vision for the Future: Enhancing Decentralized Clinical Trials
Since its inception in 2015, Trialogics has championed the decentralization of clinical trials. The company’s vision has always included the ability to capture patient data remotely, and this approach aligns seamlessly with the changing dynamics of the clinical trial landscape.
With headquarters in Wilmington, Delaware, and offices in Rome, London, and an upcoming office in Sydney, Trialogics is well-positioned to continue its mission of transforming the clinical trial experience. By offering integrated solutions, pioneering technology, and a global presence, Trialogics is paving the way for a future of more efficient, effective, and patient-centric clinical trials.
About Trialogics: Empowering Faster Cures
Founded in 2015 by CEO Christopher Gropp, Trialogics is a Delaware-based clinical trial software company. With an impressive portfolio that includes eConsent, IRT (RTSM), eCOA, and Remote Device Management, Trialogics is committed to providing comprehensive solutions for global clinical trials. The company’s integrated approach reflects its focus on decentralized clinical trials, with the ability to capture patient data remotely at its core. Headquartered in Wilmington, Delaware, Trialogics has expanded its footprint to Rome, London, and soon, Sydney. For more information, please visit trialogics.com.
